Christina A. Mikosz

Patterns of postoperative opioid dispensing among Medicaid beneficiaries, 2016–2017 and 2021–2022

Yi-Wen Shih, Kun Zhang, Kristine M Schmit, Deborah Dowell et autres

us (code pays fourni par la source)

Assessment of High-Volume Antibiotic and Opioid Prescribing by Medicare Part D Prescribers―United States, 2021

Axel A Vazquez Deida, Christine Kim, Katryna A. Gouin, Kun Zhang et autres

Characterizing high-volume co-prescribing of antibiotics and opioids can inform interventions that improve prescribing practices. Using 2021 Medicare Part D data, we conducted a cross-sectional analysis to assess concordance between high-volume prescribing of antibiotics and opioids and characterize associations between prescriber-level factors and …

us (code pays fourni par la source)

Opioid Dispensing Trends Among Children and Adolescents Aged ≤ 19 Years in the United States: 2018–2022

Ceciley Bly, Gery P. Guy, Christina A. Mikosz, Andrew Terranella

us (code pays fourni par la source)

Economic Costs of Chronic Pain—United States, 2021

Gery P. Guy, Gabrielle F. Miller, Jaswinder K. Legha, S. Michaela Rikard et autres

BACKGROUND: Chronic pain affects more than 1 in 5 adults in the United States. Understanding the economic burden of chronic pain can inform interventions and strategies to improve the quality of life for individuals with chronic pain. OBJECTIVE: To estimate the economic …

Ouganda, Kenya, us (code pays fourni par la source)

The Mainstreaming Addiction Treatment Act and Pharmacist-Prescribed Buprenorphine

Emmy L. Tran, S. Michaela Rikard, Gery P. Guy, Christina A. Mikosz

This study examines the impact of the MAT Act on trends in pharmacist-prescribed buprenorphine from US retail pharmacies from 2019 to 2024.

us (code pays fourni par la source)

Substance Use Screening, Brief Intervention, and Referral to Treatment Among Youth-Serving Clinicians

Kathleen R Ragan-Burnett, Lyna Z. Schieber, Andrew Terranella, Christina A. Mikosz

Importance: Despite decreasing substance use by adolescents in recent years, overdose rates continue to rise. Morbidity and mortality from substance use is preventable if detected; however, screening practices among youth-serving clinicians are unknown. Objective: To describe youth-serving clinicians' screening, brief intervention, and …

us (code pays fourni par la source)

Overdoses Involving Medetomidine Mixed with Opioids — Chicago, Illinois, May 2024

Amy Nham, John M. Le, Shawn A. Thomas, Kimberly Gressick et autres

Medetomidine, a nonopioid sedative not approved for use in humans, has periodically been detected in illegally manufactured opioids across North America since 2022. On May 11, 2024, the Chicago Department of Public Health (CDPH) and the Illinois Department of Public Health were …

us (code pays fourni par la source)

Naloxone Dispensing to Youth Ages 10–19: 2017–2022

Andrew Terranella, Gery P. Guy, Christina A. Mikosz

BACKGROUND AND OBJECTIVES: Naloxone is lifesaving in the event of an opioid overdose but is underutilized in adolescents. Youth-serving clinicians can play a role in expanding naloxone access by offering it to all youth at risk for opioid-involved overdose, including by prescription. …

us (code pays fourni par la source)

Physicians’ Self-Reported Knowledge and Behaviors Related to Prescribing Opioids for Chronic Pain and Diagnosing Opioid Use Disorder, DocStyles, 2020

Kathleen R Ragan-Burnett, Clayton Curtis, Kristine M Schmit, Christina A. Mikosz et autres

Introduction In 2016, the Centers for Disease Control and Prevention released the Guideline for Prescribing Opioids for Chronic Pain (2016 Centers for Disease Control and Prevention Guideline) to improve opioid prescribing while minimizing associated risks. This analysis sought to understand guideline-concordant knowledge …

us (code pays fourni par la source)

Pattern of Buprenorphine Treatment Retention Among Youth Aged 10 to 18 Years—US, 2015 to 2021

Sarah Connolly, Andrew Terranella, Gery P. Guy, Christina A. Mikosz

This cohort study investigates patterns of buprenorphine treatment retention among US youth aged 10 to 18 years from 2015 to 2021.

us (code pays fourni par la source)

Reported Xylazine Use Among Adults Aged ≥18 Years Evaluated for Substance Use Treatment — United States, July 2022–September 2023

Xinyi Jiang, Sarah Connolly, Andrea E. Strahan, Liz Rivera Blanco et autres

Xylazine has been increasingly detected in illegally manufactured fentanyl (IMF) products and overdose deaths in the United States; most xylazine-involved overdose deaths involve IMF. A convenience sample of U.S. adults aged ≥18 years was identified from those evaluated for substance use treatment …

Treatment for Opioid Use Disorder: Population Estimates — United States, 2022

Deborah Dowell, Samantha M. Brown, Shiromani Gyawali, Jennifer M. Hoenig et autres

In 2022, 81,806 opioid-involved overdose deaths were reported in the United States, more than in any previous year. Medications for opioid use disorder (OUD), particularly buprenorphine and methadone, substantially reduce overdose-related and overall mortality. However, only a small proportion of persons with …

us (code pays fourni par la source)